2007 completed, 343 unknown, 193 terminated, 99 withdrawn. 582 Phase 2, 475 Phase 3, 442 Phase 1, 368 Not applicable, 331 Phase 4.
Follow Flaviviridae Infections: new trials by email Literature Review of Flaviviridae Infections trials Research Report on Flaviviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans Integrated care - Opioid Use Disorder, HIV | Not applicable | Not yet recruiting | VA Office of Research and Development | 60 | 2028-04-03 | 2026-04-24 |
| STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine Standard of Care (Patient Navigation to Off-Site Clinic), Status-Neutral Telehealth Concierge (SN-THR) - HIV, Substance Use Disorder (SUD) | Not applicable | Not yet recruiting | University of Miami | 200 | 2027-05-01 | 2026-11-12 |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, INSTI HIV - 1/2 Antibody, bioLytical Laboratories iStatis Hepatitis B Surface Antigen Test - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-11-17 |
| A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) AVIHepC1, Normal Saline - Hepatitis C | Phase 1 | Not yet recruiting | University of Alberta | 27 | 2027-01-15 | 2026-09-25 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) - Hepatitis C | Not applicable | Not yet recruiting | Johns Hopkins University | 200 | 2026-11-01 | 2025-11-10 |
| Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue | Not yet recruiting | Liverpool School of Tropical Medicine | 235 | 2026-11-01 | 2026-09-02 | |
| Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 388 | 2026-11-01 | 2026-10-29 |
| Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 1660 | 2026-11-01 | 2026-10-29 |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Strengthening, Guidance, Health, Empowerment Self-sampling for six sexually transmitted infections - HIV Infection, Syphilis | Not applicable | Not yet recruiting | University Hospital, Montpellier | 200 | 2026-09-01 | 2026-08-26 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs Partner navigation intervention booster session - HEPATITIS C (HCV), Opioid Use Disorder | Not applicable | Not yet recruiting | University of California, San Francisco | 50 | 2026-09-01 | 2026-06-08 |
| Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants Skin punch biopsy, Blood samples - Yellow Fever (Healthy Volunteers), Biopsy/Methods | Not applicable | Recruiting | Institute of Tropical Medicine, Belgium | 40 | 2026-08-10 | 2026-08-13 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3) Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID) - HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV) | Not applicable | Not yet recruiting | University of Georgia | 50 | 2026-08-01 | 2025-12-18 |
Showing 20 of 2813. Sign in to see all of them.
Hepatitis C (1722) · Hepatitis C, Chronic (907) · Dengue (275) · HIV Infections (131) · Hepatitis B (107) · Fibrosis (102) · Acquired Immunodeficiency Syndrome (93) · Hepatitis (86) · Zika Virus Infection (77) · Liver Diseases (74) · Encephalitis, Japanese (72) · Liver Cirrhosis (67) · Severe Dengue (65) · Carcinoma, Hepatocellular (58) · Encephalitis, Tick-Borne (51)
RNA Virus Infections (2794) · Infections (2786) · Virus Diseases (2762) · Blood-Borne Infections (2316) · Communicable Diseases (2304) · Digestive System Diseases (2304) · Hepatitis, Viral, Human (2297) · Liver Diseases (2242) · Hepatitis (2230) · Pathological Conditions, Signs and Symptoms (1135) · Pathologic Processes (1112) · Disease Attributes (988) · Chronic Disease (950) · Hepatitis, Chronic (897)
Ribavirin (657) · peginterferon alfa-2a (306) · Sofosbuvir (173) · peginterferon alfa-2b (155) · daclatasvir (99) · sofosbuvir-velpatasvir drug combination (79) · Simeprevir (72) · telaprevir (71) · ledipasvir, sofosbuvir drug combination (68) · paritaprevir (61) · ombitasvir (59) · Ritonavir (56) · dasabuvir (54) · grazoprevir (50) · glecaprevir and pibrentasvir (49)
Merck Sharp & Dohme LLC (164) · Gilead Sciences (119) · AbbVie (91) · Bristol-Myers Squibb (91) · National Institute of Allergy and Infectious Diseases (NIAID) (90) · Hoffmann-La Roche (89) · Sanofi Pasteur, a Sanofi Company (49) · ANRS, Emerging Infectious Diseases (33) · National Taiwan University Hospital (33) · Kirby Institute (32) · Pfizer (32) · Tibotec Pharmaceuticals, Ireland (29) · Boehringer Ingelheim (28) · Vertex Pharmaceuticals Incorporated (28) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (26)
United States (971) · France (260) · Germany (210) · Canada (192) · Puerto Rico (181) · Spain (171) · Australia (155) · United Kingdom (148) · Italy (110) · Belgium (107) · Taiwan (103) · Brazil (101) · Egypt (93) · Poland (89) · Austria (86)
Anna Durbin, MD (30) · Chen-Hua Liu, MD (16)
PMID 30739368, PMID 30977945, PMID 40099800, PMID 30012435, PMID 30923816, PMID 28193518, PMID 29461687, PMID 31568620, PMID 30529905, PMID 29377566, PMID 29404492, PMID 25445400, PMID 30868245, PMID 42253092, PMID 23607594, PMID 24209977, PMID 25040192, PMID 25583164, PMID 26214039, PMID 26575258, PMID 26683763, PMID 27847279, PMID 29897841, PMID 33822015, PMID 35174470, PMID 37096802, PMID 22821361, PMID 23607593, PMID 24329937, PMID 26383952, PMID 26743093, PMID 26947564, PMID 27553375, PMID 29217375, PMID 31878895, PMID 36740893, PMID 39116904, PMID 12823087, PMID 16122679, PMID 17552026, PMID 18054553, PMID 20130466, PMID 20189674, PMID 20199501, PMID 20934459, PMID 20951424, PMID 21488067, PMID 21592984, PMID 21688284, PMID 22239511
2014 (40), 2015 (35), 2009 (22), 2016 (18), 2008 (11), 2004 (7), 2005 (7), 2019 (6), 2018 (5), 2017 (3), U01DK062498 (3), UL1TR001082 (3), UM1AI068636 (3), 2023 (2), P30AI042853 (2)